CN1126541C - 新型复合氨基酸组合物 - Google Patents
新型复合氨基酸组合物 Download PDFInfo
- Publication number
- CN1126541C CN1126541C CN 99125545 CN99125545A CN1126541C CN 1126541 C CN1126541 C CN 1126541C CN 99125545 CN99125545 CN 99125545 CN 99125545 A CN99125545 A CN 99125545A CN 1126541 C CN1126541 C CN 1126541C
- Authority
- CN
- China
- Prior art keywords
- amino acid
- compound amino
- wound
- nutritional support
- glutamine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 30
- -1 Compound amino acid Chemical class 0.000 title claims abstract description 25
- 235000001014 amino acid Nutrition 0.000 claims abstract description 61
- 150000001413 amino acids Chemical class 0.000 claims abstract description 37
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims abstract description 25
- 235000016709 nutrition Nutrition 0.000 claims abstract description 22
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims abstract description 18
- 150000005693 branched-chain amino acids Chemical class 0.000 claims abstract description 16
- 229960003080 taurine Drugs 0.000 claims abstract description 9
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims abstract description 7
- 229940024606 amino acid Drugs 0.000 claims description 60
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 31
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 16
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 16
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 13
- 239000002131 composite material Substances 0.000 claims description 12
- 238000002360 preparation method Methods 0.000 claims description 11
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 10
- 229960003136 leucine Drugs 0.000 claims description 10
- 239000007788 liquid Substances 0.000 claims description 10
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 9
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 9
- 229960003767 alanine Drugs 0.000 claims description 9
- 229960004295 valine Drugs 0.000 claims description 9
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 8
- 239000004471 Glycine Substances 0.000 claims description 8
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 8
- 229960005261 aspartic acid Drugs 0.000 claims description 8
- CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 claims description 6
- CKLJMWTZIZZHCS-UWTATZPHSA-N L-Aspartic acid Natural products OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 claims description 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 6
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 claims description 5
- HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical group C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 claims description 5
- 108010016626 Dipeptides Proteins 0.000 claims description 5
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 5
- 239000004473 Threonine Substances 0.000 claims description 5
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 5
- 235000004279 alanine Nutrition 0.000 claims description 5
- 229960002989 glutamic acid Drugs 0.000 claims description 5
- 229960000310 isoleucine Drugs 0.000 claims description 5
- 239000004474 valine Substances 0.000 claims description 5
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 claims description 4
- QNAYBMKLOCPYGJ-UWTATZPHSA-N L-Alanine Natural products C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 claims description 4
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims description 4
- 229930064664 L-arginine Natural products 0.000 claims description 4
- 235000014852 L-arginine Nutrition 0.000 claims description 4
- 229930182844 L-isoleucine Natural products 0.000 claims description 4
- 239000004395 L-leucine Substances 0.000 claims description 4
- 235000019454 L-leucine Nutrition 0.000 claims description 4
- 239000004472 Lysine Substances 0.000 claims description 4
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 4
- 229960002885 histidine Drugs 0.000 claims description 4
- 239000000463 material Substances 0.000 claims description 4
- 229960004441 tyrosine Drugs 0.000 claims description 4
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 3
- 229960002648 alanylglutamine Drugs 0.000 claims description 3
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 2
- 229960002449 glycine Drugs 0.000 claims description 2
- PNMUAGGSDZXTHX-UHFFFAOYSA-N glycyl-glutamine Chemical compound NCC(=O)NC(C(O)=O)CCC(N)=O PNMUAGGSDZXTHX-UHFFFAOYSA-N 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 18
- 208000027418 Wounds and injury Diseases 0.000 abstract description 17
- 206010052428 Wound Diseases 0.000 abstract description 15
- 239000007924 injection Substances 0.000 abstract description 13
- 238000002347 injection Methods 0.000 abstract description 13
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract description 12
- 230000029663 wound healing Effects 0.000 abstract description 9
- 229910052757 nitrogen Inorganic materials 0.000 abstract description 6
- 230000007774 longterm Effects 0.000 abstract description 4
- 235000018102 proteins Nutrition 0.000 abstract description 4
- 102000004169 proteins and genes Human genes 0.000 abstract description 4
- 108090000623 proteins and genes Proteins 0.000 abstract description 4
- 208000015181 infectious disease Diseases 0.000 abstract description 3
- 108010044940 alanylglutamine Proteins 0.000 abstract description 2
- 230000015556 catabolic process Effects 0.000 abstract description 2
- 230000001737 promoting effect Effects 0.000 abstract description 2
- 235000003704 aspartic acid Nutrition 0.000 abstract 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 abstract 1
- 238000006731 degradation reaction Methods 0.000 abstract 1
- 239000004615 ingredient Substances 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 238000005728 strengthening Methods 0.000 abstract 1
- 241000700159 Rattus Species 0.000 description 16
- 208000014674 injury Diseases 0.000 description 15
- 235000020776 essential amino acid Nutrition 0.000 description 13
- 239000003797 essential amino acid Substances 0.000 description 13
- 230000008733 trauma Effects 0.000 description 13
- 230000036737 immune function Effects 0.000 description 7
- 210000002381 plasma Anatomy 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 5
- 210000004400 mucous membrane Anatomy 0.000 description 5
- 210000000813 small intestine Anatomy 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 102000008186 Collagen Human genes 0.000 description 4
- 108010035532 Collagen Proteins 0.000 description 4
- 230000000968 intestinal effect Effects 0.000 description 4
- 210000004347 intestinal mucosa Anatomy 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- 108020004707 nucleic acids Proteins 0.000 description 4
- 102000039446 nucleic acids Human genes 0.000 description 4
- 150000007523 nucleic acids Chemical class 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 210000004165 myocardium Anatomy 0.000 description 3
- 230000035764 nutrition Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 210000002027 skeletal muscle Anatomy 0.000 description 3
- 230000036558 skin tension Effects 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 206010003694 Atrophy Diseases 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- 230000037444 atrophy Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000006866 deterioration Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 235000016236 parenteral nutrition Nutrition 0.000 description 2
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 102000008934 Muscle Proteins Human genes 0.000 description 1
- 108010074084 Muscle Proteins Proteins 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 102000011195 Profilin Human genes 0.000 description 1
- 108050001408 Profilin Proteins 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- ODHCTXKNWHHXJC-GSVOUGTGSA-N Pyroglutamic acid Natural products OC(=O)[C@H]1CCC(=O)N1 ODHCTXKNWHHXJC-GSVOUGTGSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- ODHCTXKNWHHXJC-UHFFFAOYSA-N acide pyroglutamique Natural products OC(=O)C1CCC(=O)N1 ODHCTXKNWHHXJC-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 125000001980 alanyl group Chemical group 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000009697 arginine Nutrition 0.000 description 1
- 238000006701 autoxidation reaction Methods 0.000 description 1
- 229960000796 barbital sodium Drugs 0.000 description 1
- FTOAOBMCPZCFFF-UHFFFAOYSA-N barbitone sodium Natural products CCC1(CC)C(=O)NC(=O)NC1=O FTOAOBMCPZCFFF-UHFFFAOYSA-N 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000001217 buttock Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000014105 formulated food Nutrition 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000000527 lymphocytic effect Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000003863 physical function Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- RGHFKWPGWBFQLN-UHFFFAOYSA-M sodium;5,5-diethylpyrimidin-3-ide-2,4,6-trione Chemical compound [Na+].CCC1(CC)C([O-])=NC(=O)NC1=O RGHFKWPGWBFQLN-UHFFFAOYSA-M 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
Images
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims (18)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 99125545 CN1126541C (zh) | 1999-12-03 | 1999-12-03 | 新型复合氨基酸组合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 99125545 CN1126541C (zh) | 1999-12-03 | 1999-12-03 | 新型复合氨基酸组合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1298701A CN1298701A (zh) | 2001-06-13 |
CN1126541C true CN1126541C (zh) | 2003-11-05 |
Family
ID=5283997
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 99125545 Expired - Lifetime CN1126541C (zh) | 1999-12-03 | 1999-12-03 | 新型复合氨基酸组合物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1126541C (zh) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR0215904A (pt) * | 2002-10-08 | 2005-08-09 | Abbott Lab | Métodos e composições para prover glutamina |
ES2282880T3 (es) * | 2003-05-22 | 2007-10-16 | N.V. Nutricia | Metodo para tratar o prevenir heridas cronicas y composicion nutritiv a completa comprendiendo glicina y/o leucina para usar en este. |
CN1320091C (zh) * | 2005-01-06 | 2007-06-06 | 唐荣昌 | 一种含有二肽的白酒及其制备方法 |
CN100344231C (zh) * | 2005-09-16 | 2007-10-24 | 广东省农业科学院土壤肥料研究所 | 一种氨基酸配合物叶面肥的配制方法 |
CN100371317C (zh) * | 2006-08-07 | 2008-02-27 | 江阴南极星生物制品有限公司 | 牛磺酸精氨酸盐的合成方法 |
CN102578567A (zh) * | 2011-11-25 | 2012-07-18 | 天津天狮生物发展有限公司 | 一种补充氨基酸、增强免疫功能的保健食品及其制备方法 |
CN102488685B (zh) * | 2011-12-30 | 2013-05-01 | 贵州扬生医用器材有限公司 | 含复方氨基酸成分的脂质体制剂的应用方法 |
DK3226854T3 (da) * | 2014-12-04 | 2020-03-23 | Professional Dietetics Int S R L In Forma Abbreviata P D Int S R L | Aminosyrebaseret sammensætning til genoprettelse af fibroelastin i hudens bindevæv |
CN106309486A (zh) * | 2016-08-25 | 2017-01-11 | 吴文国 | 营养组合物及在制备器官损伤修复药物中的应用 |
TW201932483A (zh) * | 2018-01-16 | 2019-08-16 | 林文欽 | 用於形成膠原蛋白的氨基酸組成物 |
CN108618993B (zh) * | 2018-07-16 | 2021-07-27 | 广东格烯生物科技股份有限公司 | 一种美白组合物及其制备方法和应用 |
CN113475721A (zh) * | 2021-06-24 | 2021-10-08 | 重庆市急救医疗中心 | 一种用于多发伤患者的肠内营养制剂 |
-
1999
- 1999-12-03 CN CN 99125545 patent/CN1126541C/zh not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
CN1298701A (zh) | 2001-06-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5889040A (en) | Composition for increasing protein concentration in a mammal | |
CN1126541C (zh) | 新型复合氨基酸组合物 | |
US3950529A (en) | Amino acid formulations for patients with liver disease and method of using same | |
US5863906A (en) | Composition based on amino acids intended for the treatment of sepsis or of an attack bringing about an inflammatory reaction, in animals and man | |
JP5315996B2 (ja) | 総合経腸栄養組成物 | |
JP4815752B2 (ja) | アミノ酸含有飲食品 | |
EP0547099B1 (en) | Product containing growth factor and glutamine and use of growth factor for the treatment of intestinal mucosa | |
EP0758234A1 (en) | Method and composition for treating renal disease and failure | |
CN101420933A (zh) | 用于胃肠外营养的儿科氨基酸溶液 | |
CN101049500A (zh) | 一种氨基酸组合物 | |
EP0182356B1 (en) | Nutrient compositions | |
JPS60255722A (ja) | 糖尿病用アミノ酸輸液 | |
EP0457314A1 (en) | Nutrient compositions containing peptides | |
JP4011638B2 (ja) | 経口経腸栄養組成物 | |
CA2134380C (en) | Composition based on amino acids intended for the treatment of sepsis or of an attack bringing about an inflammatory reaction, in animals and man | |
EP0502313A2 (en) | Method for insuring adequate intracellular glutathione in tissue | |
EP0656178B1 (en) | Nutritional compositions for management of nitrogen metabolism | |
JP3914585B2 (ja) | マクロファージ一酸化窒素産生亢進剤 | |
JPH07330583A (ja) | 遊離型グルタミン酸を含有する液状製剤 | |
JP2683129B2 (ja) | 栄養組成物 | |
JP2017523203A (ja) | 海産物ペプチドおよび魚類ヌクレオチド、その組成物および血糖を低下させるためのその使用 | |
JPH07267855A (ja) | グルタミン産生剤 | |
WO2009035333A1 (en) | Bioactive amino acids as growth stimulating nutraceutica in salmon | |
JPH02119762A (ja) | L−グルタミンのオリゴペプチド配合栄養組成物 | |
JPH02138952A (ja) | L−ロイシンのジペプチドを含有する栄養輸液組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C06 | Publication | ||
PB01 | Publication | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: GUANGZHOU BEIKENENG BIOLOGY SCIENCE DEVELOPMENT C Free format text: FORMER OWNER: NONE Effective date: 20040806 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20040806 Address after: 100850 No. 27 Taiping Road, Beijing, Haidian District Co-patentee after: Guangzhou Beckonen Biotechnology Development Co.,Ltd. Patentee after: Institute of Radiation Medicine, Chinese Academy of Military Medical Sciences Address before: 100850 No. 27 Taiping Road, Beijing, Haidian District Patentee before: Institute of Radiation Medicine, Chinese Academy of Military Medical Sciences |
|
EE01 | Entry into force of recordation of patent licensing contract |
Assignee: Guangzhou Beckonen Biotechnology Development Co.,Ltd. Assignor: Institute of Radiation Medicine, Chinese Academy of Military Medical Sciences Contract fulfillment period: 2004-03-05 to the contract period Contract record no.: 041000030030 Denomination of invention: Novel compound amino acid composition Granted publication date: 20031105 License type: Exclusive license Record date: 20040511 |
|
LIC | Patent licence contract for exploitation submitted for record |
Free format text: EXCLUSIVE LICENCE; TIME LIMIT OF IMPLEMENTING CONTACT:2004-03-05 TO CONTRACT Name of requester: GUANGZHOU BEIKENENG BIOLOGY SCIENCE DEVELOPMENT C Effective date: 20040511 |
|
C41 | Transfer of patent application or patent right or utility model | ||
C56 | Change in the name or address of the patentee | ||
CP01 | Change in the name or title of a patent holder |
Address after: 100850 Taiping Road, Beijing, Haidian District, No. 27 Patentee after: INSTITUTE OF RADIATION MEDICINE, ACADEMY OF MILITARY MEDICAL SCIENCES, PLA Patentee after: Guangzhou Beckonen Biotechnology Development Co.,Ltd. Address before: 100850 Taiping Road, Beijing, Haidian District, No. 27 Patentee before: Institute of Radiation Medicine, Chinese Academy of Military Medical Sciences Patentee before: Guangzhou Beckonen Biotechnology Development Co.,Ltd. |
|
TR01 | Transfer of patent right |
Effective date of registration: 20150924 Address after: 100850 Taiping Road, Beijing, Haidian District, No. 27 Patentee after: INSTITUTE OF RADIATION MEDICINE, ACADEMY OF MILITARY MEDICAL SCIENCES, PLA Patentee after: BEIJING SCIECURE PHARMACEUTICAL Co.,Ltd. Address before: 100850 Taiping Road, Beijing, Haidian District, No. 27 Patentee before: INSTITUTE OF RADIATION MEDICINE, ACADEMY OF MILITARY MEDICAL SCIENCES, PLA Patentee before: Guangzhou Beckonen Biotechnology Development Co.,Ltd. |
|
CX01 | Expiry of patent term | ||
CX01 | Expiry of patent term |
Granted publication date: 20031105 |